论文部分内容阅读
为了评价和观察伊立替康(CPT-11)联合氟尿嘧啶(5-FU)与亚叶酸钙(LV)双周方案(FOLFIRI)治疗转移性结直肠癌的临床疗效和不良反应,对56例转移性结直肠癌患者采用FOLFIRI双周方案治疗,剂量为CPT-11180mg/m2,静脉滴入90min,d1,LV200mg/m2,静脉滴入,d1,d2,5-FU400mg/m2,静脉推注,d1,d2,5-FU600mg/m2,持续静脉滴入22h,d1,d2,14d为1个周期。54例可评价疗效,CR1例,PR17例,SD23例,PD13例,有效率33.3%。不良反应主要为延迟性腹泻、中性粒细胞减少及胆碱能综合征。初步研究结果提示,FOLFIRI双周方案治疗转移性结直肠癌疗效肯定,安全性好,不良反应可耐受,值得临床推广应用。
To evaluate and observe the clinical efficacy and adverse reactions of irinotecan (CPT-11) combined with 5-fluorouracil (5-FU) and leucovorin (LV) biweekly regimen (FOLFIRI) in the treatment of metastatic colorectal cancer, 56 cases of metastatic Colorectal cancer patients were treated with FOLFIRI biweekly regimen. The dose was CPT-11180mg / m2, intravenous infusion 90min, d1, LV200mg / m2, intravenous infusion, d1, d2,5-FU400mg / d2,5-FU600mg / m2, continuous intravenous infusion of 22h, d1, d2, 14d for a cycle. 54 cases can be evaluated curative effect, CR1 cases, PR17 cases, SD23 cases, PD13 cases, the effective rate was 33.3%. Adverse reactions are mainly delayed diarrhea, neutropenia and cholinergic syndrome. Preliminary results suggest that, FOLFIRI biweekly regimen for the treatment of metastatic colorectal cancer is positive, safe, and adverse reactions are tolerable, worthy of clinical promotion and application.